[go: up one dir, main page]

WO2004020577A3 - Processes for inhibiting gene expression using polynucleotides - Google Patents

Processes for inhibiting gene expression using polynucleotides Download PDF

Info

Publication number
WO2004020577A3
WO2004020577A3 PCT/US2003/015643 US0315643W WO2004020577A3 WO 2004020577 A3 WO2004020577 A3 WO 2004020577A3 US 0315643 W US0315643 W US 0315643W WO 2004020577 A3 WO2004020577 A3 WO 2004020577A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene expression
polynucleotides
processes
inhibiting gene
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/015643
Other languages
French (fr)
Other versions
WO2004020577A2 (en
Inventor
David L Lewis
David B Rozema
Jon A Wolff
James E Hagstrom
Hans Herweijer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arrowhead Madison Inc
Original Assignee
Mirus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirus Corp filed Critical Mirus Corp
Priority to EP03751760A priority Critical patent/EP1506020A4/en
Publication of WO2004020577A2 publication Critical patent/WO2004020577A2/en
Publication of WO2004020577A3 publication Critical patent/WO2004020577A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A process is provided for inhibition of specific gene expression in an animal cell by delivering a combination of RNA function inhibitors. Using a combination of inhibitors results in improved efficacy of gene expression inhibition. The process can be used to reduce gene expression in cells in vitro and in vivo.
PCT/US2003/015643 2002-05-23 2003-05-19 Processes for inhibiting gene expression using polynucleotides Ceased WO2004020577A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP03751760A EP1506020A4 (en) 2002-05-23 2003-05-19 Processes for inhibiting gene expression using polynucleotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38284202P 2002-05-23 2002-05-23
US60/382,842 2002-05-23

Publications (2)

Publication Number Publication Date
WO2004020577A2 WO2004020577A2 (en) 2004-03-11
WO2004020577A3 true WO2004020577A3 (en) 2004-09-23

Family

ID=31978209

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/015643 Ceased WO2004020577A2 (en) 2002-05-23 2003-05-19 Processes for inhibiting gene expression using polynucleotides

Country Status (2)

Country Link
EP (1) EP1506020A4 (en)
WO (1) WO2004020577A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUNTER ET AL: "Genetics: A touch of elegance with RNAi", CURR. BIOLOGY, vol. 9, no. 12, June 1999 (1999-06-01), pages R440 - R442, XP002211290 *
See also references of EP1506020A4 *
SIROIS ET AL: "Antisense oligonucleotide inhibition of PDGFR-beta receptor subunit expression directs suppression of intimal thickening", CIRCULATION, vol. 95, no. 3, 4 February 1997 (1997-02-04), pages 669 - 676, XP002967163 *

Also Published As

Publication number Publication date
EP1506020A2 (en) 2005-02-16
EP1506020A4 (en) 2007-08-29
WO2004020577A2 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
WO2003080794A3 (en) Inhibition of rna function by delivery of inhibitors to animal cells
WO2005009346A3 (en) Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
MXPA02004233A (en) Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues.
MXPA06010900A (en) Inhibitors of histone deacetylase.
WO2004065564A3 (en) Electromagnetic activation of gene expression and cell growth
GB0007371D0 (en) Chemical compounds
GEP20084395B (en) PYRROLO [3,4-c] PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
IL158543A0 (en) Homing of embryonic stem cells to a target zone in tissue using active therapeutics of substances
WO2004050826A3 (en) Method of dynamically culturing embryonic stem cells
WO2007100895A3 (en) Cancer treatment with gamma-secretase inhibitors
AU2003221584A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
IL173236A0 (en) Plant cell cycle genes and methods of use
AU3772000A (en) Selective inhibition of cyclooxygenase-2
AUPS112802A0 (en) Methods of inducing differentiation of stem cells into a specific cell lineage
ATE446373T1 (en) SEQUENCE-SPECIFIC DNA RECOMBINATION IN EUKARYOTIC CELLS
WO2004072248A3 (en) A process for delivering sirna to cardiac muscle tissue
WO2005017098A3 (en) AMPHIPATHIC AND POLYCATIONIC COMPOUNDS FOR DELIVERING siRNA
WO2009072635A1 (en) Method for amplifying hematopoietic stem cells using heterocyclic compound
WO2009072625A1 (en) Amplification method for hematopoietic stem cells with heterocyclic compound
MX2007008980A (en) Nucleic acids for apoptosis of cancer cells.
WO2000047231A3 (en) Novel antisense inhibition of rad51
WO2004020577A3 (en) Processes for inhibiting gene expression using polynucleotides
WO2004003152A3 (en) Sos1 inhibitors
MXPA05011435A (en) 5-hydroxyindoles with n-oxide groups and use thereof as a phosphodiesterase 4 inhibitor.
WO2003099228A8 (en) Compositions and processes for inhibiting gene expression using polynucleotides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003751760

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003751760

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP